Laurion Capital Management LP United Therapeutics Corp Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$228.26 - $319.04 $194,934 - $272,460	854 New	854 $272,000
Q3 2020 Nov 13, 2020	SELL	$99.9 - $121.13 $213,985 - $259,460	-2,142 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$92.74 - $125.82 $198,649 - $269,506	2,142 New	2,142 $259,000
Q1 2020 May 14, 2020	SELL	$79.39 - $115.35 $1.6 Million - $2.32 Million	-20,100 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$78.31 - $95.34 $1.57 Million - $1.92 Million	20,100 New	20,100 $1.77 Million
Q3 2018 Nov 13, 2018	SELL	$113.81 - $129.46 $379,214 - $431,360	-3,332 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$101.14 - $118.31 $155,755 - $182,197	1,540 Added 85.94%	3,332 $377,000
Q1 2018 May 14, 2018	SELL	$107.21 - $151.94 $1.2 Million - $1.7 Million	-11,200 Reduced 86.21%	1,792 $201,000
Q4 2017 Feb 13, 2018	BUY	$118.58 - $151.28 $166,012 - $211,792	1,400 Added 12.08%	12,992 $1.92 Million
Q3 2017 Nov 13, 2017	BUY	$114.6 - $136.81 $1.33 Million - $1.59 Million	11,592	11,592 $1.36 Million

668

42.8M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.